These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34581997)

  • 1. Exploring How and Why to Develop Patient-Centered Packaging: A Multiple-Case Study with Pharmaceutical Companies.
    Carli Lorenzini G; Olsson A
    Ther Innov Regul Sci; 2022 Jan; 56(1):117-129. PubMed ID: 34581997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Do Pharmaceutical Companies Overcome a Corporate Productivity Crisis? Business Diversification into Medical Devices for Growth Potential.
    Euh Y; Lee D
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33503944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Centricity and Pharmaceutical Companies: Is It Feasible?
    du Plessis D; Sake JK; Halling K; Morgan J; Georgieva A; Bertelsen N
    Ther Innov Regul Sci; 2017 Jul; 51(4):460-467. PubMed ID: 30227057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug packaging in 2014: authorities should direct more efforts towards medication safety.
    Prescrire Int; 2015 May; 24(160):136-8. PubMed ID: 26034808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uniting Discovery and Care: The Role of Pharmaceutical Companies in Research, Clinical Studies, and Patient Care.
    Tan C; McGill JM; Mallbris L
    J Invest Dermatol; 2020 Mar; 140(3):527-530. PubMed ID: 31972248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.
    Parker L; Fabbri A; Grundy Q; Mintzes B; Bero L
    BMJ; 2019 Dec; 367():l6694. PubMed ID: 31831471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations.
    Hansen MB; Nørgaard LS; Hallgreen CE
    Ther Innov Regul Sci; 2020 May; 54(3):577-585. PubMed ID: 33301145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges encountered in the conduct of Optimal Health: A patient-centered comparative effectiveness study of interventions for adults with serious mental illness.
    Kogan JN; Schuster J; Nikolajski C; Schake P; Carney T; Morton SC; Kang C; Reynolds CF
    Clin Trials; 2017 Feb; 14(1):5-16. PubMed ID: 27681658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short communication: a study on the packaging information of essential drug products used at Union and Thana health complex level in Bangladesh.
    Amran S; Ahmed M; Shaheen SM; Morshed SN; Khandakar J; Rahman M; Rahman M; Hossain A
    Pak J Pharm Sci; 2007 Oct; 20(4):327-32. PubMed ID: 17604258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining patient centricity with patients for patients and caregivers: a collaborative endeavour.
    Yeoman G; Furlong P; Seres M; Binder H; Chung H; Garzya V; Jones RR
    BMJ Innov; 2017 Apr; 3(2):76-83. PubMed ID: 28890797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing stakeholder opinion on relations between cancer patient groups and pharmaceutical companies in Europe.
    Leto di Priolo S; Fehervary A; Riggins P; Redmond K
    Patient; 2012; 5(2):127-39. PubMed ID: 22299759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Container-content compatibility studies: a pharmaceutical team's integrated approach.
    Laschi A; Sehnal N; Alarcon A; Barcelo B; Caire-Maurisier F; Delaire M; Feuilloley M; Genot S; Lacaze C; Pisarik L; Smati C
    PDA J Pharm Sci Technol; 2009; 63(4):285-93. PubMed ID: 20088243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics, risk management and GMP standards of pharmaceutical companies in China.
    Chen H; Qin L; Jiang C; Qin M; Sun Y; Luo J
    Front Public Health; 2023; 11():1103555. PubMed ID: 36969675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal study of the impact of three major regulations on the Korean pharmaceutical industry in the last 30 years.
    Um SI; Sohn UD; Jung SY; You SH; Kim C; Lee S; Lee H
    Health Res Policy Syst; 2022 Jan; 20(1):4. PubMed ID: 34991612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respecting the right to access to medicines: Implications of the UN Guiding Principles on Business and Human Rights for the pharmaceutical industry.
    Moon S
    Health Hum Rights; 2013 Jun; 15(1):E32-43. PubMed ID: 25006088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Professional qualifications of medical affairs pharmaceutical physicians and other internal stakeholders in the pharmaceutical industry.
    Jandhyala R
    F1000Res; 2022; 11():813. PubMed ID: 36415210
    [No Abstract]   [Full Text] [Related]  

  • 20. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.